GA
Therapeutic Areas
Nanexa AB Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NEX-20 (azacitidine) | Myelodysplastic Syndromes (MDS) | Phase 1 |
| NEX-22 | Undisclosed oncology target | Preclinical |
Leadership Team at Nanexa AB
DW
David Westberg
Chief Executive Officer
AB
Anders Bull
Chief Financial Officer
JH
Johan Hjertqvist
Board Member
LS
Lena Söderström
Board Member
MG
Michaela Gertz
Board Member
FÖ
Fredrik Öberg
Chief Scientific Officer
MV
Martin Vidaeus
Head of Business Development